Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Occult Gynecologic Cancer in Hysterectomy or Myomectomy

Obstet Gynecol; ePub 2018 Mar 8; Desai, et al

Among women undergoing hysterectomies and varied by age and surgical route, prevalence of occult corpus uteri, cervical, and ovarian malignancy was 1.44%, 0.60%, and 0.19%. The secondary analysis of data from the 2014-2015 American College of Surgeons National Surgical Quality Improvement Program included 24,076 women undergoing hysterectomy and 2,368 women undergoing myomectomy. The primary outcome measure was pathology-confirmed malignancy in the corpus uteri, cervix uteri, and ovary. Researchers found:

  • Malignancy of the corpus uteri was found in 1.44% of the women undergoing hysterectomy.
  • The prevalence varied considerably across surgical routes with the rate being 0.23% in laparoscopic supracervical hysterectomy and 1.89% in total laparoscopic or laparoscopic-assisted vaginal hysterectomy.
  • Older women were significantly more like to have preoperatively undetected malignancy of the corpus uteri.

Citation:

Desai VB, Wright JD, Schwartz PE, et al. Occult gynecologic cancer in women undergoing hysterectomy or myomectomy for benign indications. [Published online ahead of print March 8, 2018]. Obstet Gynecol. doi:10.1097/AOG.0000000000002521.